Nanobiotix
Develops a physics-based, first-in-class radioenhancer for cancer treatment.
NANO | PA
Overview
Corporate Details
- ISIN(s):
- FR0010102145 (+2 more)
- LEI:
- 969500667RSYIH8YL895
- Country:
- France
- Address:
- 60 RUE DE WATTIGNIES, 75012 PARIS
- Website:
- https://www.nanobiotix.com/
- Sector:
- Manufacturing
Description
Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-15 10:47 |
Franchissement de seuils
|
French | 127.3 KB | ||
| 2025-12-15 10:37 |
Franchissement de seuils
|
French | 126.8 KB | ||
| 2025-12-15 08:30 |
NANOBIOTIX va intégrer les indices CAC Mid 60 et SBF 120 d’Euronext Paris
|
French | 156.0 KB | ||
| 2025-12-15 08:30 |
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
|
English | 102.9 KB | ||
| 2025-12-05 15:49 |
Franchissement de seuils
|
French | 127.1 KB | ||
| 2025-11-28 15:41 |
Franchissement de seuil
|
French | 125.2 KB | ||
| 2025-11-17 15:26 |
Franchissement de seuil
|
French | 124.7 KB | ||
| 2025-11-17 15:19 |
Franchissements de seuil
|
French | 143.3 KB | ||
| 2025-11-14 08:00 |
Voting Rights and Shares Capital of the Company
|
English | 113.6 KB | ||
| 2025-11-14 08:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 112.3 KB | ||
| 2025-11-13 22:15 |
NANOBIOTIX annonce les avancées de sa plateforme de nanoprimer Curadigm avec un…
|
French | 192.6 KB | ||
| 2025-11-13 22:15 |
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Pla…
|
English | 124.2 KB | ||
| 2025-11-13 18:16 |
Franchissement de seuil
|
French | 277.7 KB | ||
| 2025-11-13 18:05 |
Franchissement de seuil
|
French | 278.1 KB | ||
| 2025-11-13 17:45 |
Franchissement de seuil
|
French | 126.3 KB |
Automate Your Workflow. Get a real-time feed of all Nanobiotix filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nanobiotix
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nanobiotix via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-05-11 | N/A | Other | Other | 959,060 | N/A |
Peer Companies
